1. Home
  2. FINV vs DCTH Comparison

FINV vs DCTH Comparison

Compare FINV & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinVolution Group

FINV

FinVolution Group

N/A

Current Price

$2.85

Market Cap

668.1M

Sector

Finance

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$20.63

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FINV
DCTH
Founded
2007
1988
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
668.1M
578.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
FINV
DCTH
Price
$2.85
$20.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$5.62
★ $28.60
AVG Volume (30 Days)
★ 788.1K
653.4K
Earning Date
11-25-2026
11-09-2026
Dividend Yield
★ 11.25%
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.21
Revenue
N/A
N/A
Revenue This Year
N/A
$36.66
Revenue Next Year
N/A
$20.12
P/E Ratio
★ $3.87
$101.90
Revenue Growth
N/A
N/A
52 Week Low
$2.66
$8.12
52 Week High
$6.39
$22.51

Technical Indicators

Market Signals
Indicator
FINV
DCTH
Relative Strength Index (RSI) 44.50 72.77
Support Level N/A $10.76
Resistance Level $3.06 N/A
Average True Range (ATR) 0.13 1.10
MACD 0.00 0.81
Stochastic Oscillator 48.62 79.30

Price Performance

Historical Comparison
FINV
DCTH

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: